Skip to main content

Table 3 Predicted summary statistics (median [min–max]) of atezolizumab exposure metrics

From: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

MetricObservationBody weight dose (<  18 years)Flat dose (≥ 18 years)
<  30 kg
n = 23
30 to < 45 kg
n = 21
≥ 45 kg
n = 25
<  57 kg
n = 6
57 to < 65 kg
n = 6
≥ 65 kg
n = 6
Cmax, μg/mLCycle 1270 [182–349]330 [232–375]349 [281–407]492 [303–541]486 [419–549]326 [243–390]
Steady-state400 [277–517]463 [257–585]460 [319–618]664 [377–764]651 [505–868]404 [334–540]
Cmin, μg/mLCycle 155.6 [28.1–82.0]65.0 [20.7–91.9]65.5 [27.4–108]97.3 [47.4–122]98.8 [56.9–151]57.6 [28.4–87.5]
Steady-state120 [77.0–181]125 [25.4–246]112 [37.9–211]171 [74.1–225]164 [86.2–319]88.1 [32.4–149]
AUC, μg*day/mLCycle 12085 [1089–3053]2757 [1471–3312]2988 [1975–3954]4268 [2396–4845]4330 [3175–5448]2733 [2306–3701]
Steady-state4045 [2536–5695]4781 [1730–7295]4510 [2417–7126]6692 [3365–8125]6574 [4276–10,405]3861 [2593–5774]
CL, mL/day/kg3.72 [2.62–5.89]3.20 [2.06–8.67]3.15 [2.90–6.10]3.62 [2.61–5.20]2.90 [1.99–4.92]3.25 [1.70–5.16]
  1. Abbreviations: AUC Area under the curve, Cmax Maximum concentration, Cmin Minimum concentration, CL Clearance